Your session is about to expire
← Back to Search
Pharmacological Study for Cancer
Study Summary
This trial is testing the effects of cabozantinib s-malate on patients with solid tumors that have spread and usually can't be cured or controlled. Cabozantinib s-malate may stop tumor cell growth by blocking some enzymes needed for cell growth.
- Cancer
- Solid Tumors
- HIV/AIDS
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there a multitude of hospitals currently engaging in this research endeavor within Canada?
"UCLA Center for Clinical AIDS Research and Education in Los Angeles, California, Montefiore Medical Center-Einstein Campus in Bronx, New york, Ben Taub General Hospital in La Jolla, Ohio as well as 21 other medical centres are currently accepting participants for this clinical trial."
What is the main aim of this medical research?
"The primary end-point of this clinical trial, which will be measured over a timeline spanning up to 4 weeks, is the incidence of adverse events. Secondary outcomes include CD8+ cell count (which will use a repeated measures analysis - or Friedman's test in cases where data does not meet assumptions of normality), response rates (binomial proportions and 95% confidence intervals) and effects on HIV viral load (again using either a repeated measures analysis or Friedman's test)."
Has Cabozantinib S-malate obtained authorization from the FDA?
"Cabozantinib S-malate's safety is rated a 1 on our scale, as this trial has just reached Phase 1 and thus only contains limited data about its efficacy and safety."
How many participants can join this investigation?
"This trial is no longer in need of participants, as its last edit was made on 6/28/2022. If you are searching for other studies that may be a fit for your needs, there are currently 3708 clinical trials accepting patients with solid neoplasms and 109 trials involving Cabozantinib S-malate actively recruiting."
Has Cabozantinib S-malate been the subject of prior research projects?
"Cabozantinib S-malate was initially trialled in 2012 by Memorial Sloan Kettering Commack. So far, 643 clinical studies have been completed on the medication with 109 still ongoing, predominantly concentrated around Los Angeles, California."
What ailments does Cabozantinib S-malate typically provide relief to?
"Cabozantinib S-malate may be effective in treating advanced renal cell carcinoma (ARCC), adrenal medulla, and other conditions that have resisted anti-VEGF treatments."
Are there any open slots to join this clinical trial?
"According to clinicaltrials.gov, this specific trial is not actively recruiting patients at present and has been last updated on June 28th 2022 after initially being posted in 2013. Nevertheless, a vast 3817 medical studies are still enrolling participants right now."
Does this research break new ground in its field?
"Currently, there are 109 running clinical trials related to Cabozantinib S-malate being conducted in 1315 cities and 45 countries. This drug was first trialled in 2012 by Exelixis with a sample size of 86 participants. Since then, 643 more studies have been completed, the most recent reaching Phase 2 approval status."
Share this study with friends
Copy Link
Messenger